When Hodgkin’s disease returns after a period of wellness, it presents unique challenges—but today’s medical advances offer renewed hope through carefully tailored treatment approaches and innovative therapies being tested around the world.

Fighting Back: What Treatment Means When Hodgkin’s Lymphoma Returns

When Hodgkin’s disease comes back after treatment, doctors focus on bringing the cancer under control again and helping patients live as well as possible. The main goals include achieving another period when the disease cannot be detected, managing symptoms that may affect daily life, and preventing the cancer from causing further harm to the body. Treatment plans are never one-size-fits-all; they depend heavily on when the disease returned, how widespread it is, the patient’s age and overall health, and what treatments were already used the first time around.^[1]

Two important terms help doctors describe what’s happening when Hodgkin’s lymphoma returns. Relapsed disease means the cancer has grown or reappeared after a period when it wasn’t detectable—called remission. Refractory disease is different: it means the lymphoma never fully responded to treatment in the first place, or the response was very brief and the cancer kept growing despite therapy.^[1] Understanding which situation applies helps medical teams choose the most effective next steps.

For classical Hodgkin’s lymphoma, which is the most common type, relapses typically happen within the first three years after someone finishes their initial treatment. However, it’s important to know that some people experience a return of the disease much later—even many years down the road.^[1] The timing of relapse matters because it influences which treatment options doctors recommend and how aggressive the approach needs to be.

Even when Hodgkin’s lymphoma comes back, there is reason for optimism. Secondary therapies—meaning the treatments used after the first round—are often successful in helping patients reach another remission. In some cases, these second-line treatments may even lead to a cure, particularly when combined with advanced procedures like stem cell transplantation.^[1] Medical science has made tremendous progress in recent decades, and many people who face recurrent disease go on to live long, fulfilling lives.

Proven Treatments: The Standard Approach to Recurrent Hodgkin’s Disease

When Hodgkin’s lymphoma returns, the current standard treatment for most patients involves a carefully planned sequence of therapies. This typically begins with second-line chemotherapy—different drug combinations than were used during the first treatment—followed by a procedure called autologous stem cell transplantation, where a patient’s own stem cells are collected and then returned to their body after high-dose chemotherapy. In some situations, doctors may also recommend involved site radiation therapy, which targets specific areas where the disease is present.^[1]

The choice of which specific chemotherapy drugs to use depends on multiple factors. If the original treatment worked well and the disease stayed away for a reasonable time, doctors might consider using similar drugs again. More often, though, they select different drug combinations to attack the cancer from a new angle and overcome any resistance that may have developed.^[8] This personalized approach reflects how much has been learned about tailoring treatment to each person’s unique situation.

Several specific chemotherapy regimens have become standard options for relapsed or refractory Hodgkin’s lymphoma. One common combination is called ICE, which includes three drugs: ifosfamide, carboplatin, and etoposide. Another is DHAP, combining dexamethasone (a steroid), cisplatin, and cytarabine. A third option, ESHAP, uses etoposide, methylprednisolone (another steroid), cisplatin, and cytarabine. There’s also GVD, which brings together gemcitabine, vinorelbine, and liposomal doxorubicin—a special formulation of a chemotherapy drug. Yet another choice is IGEV, pairing ifosfamide with gemcitabine and vinorelbine.^[1][8]

Beyond combination chemotherapy, several targeted therapies and immunotherapies have become important tools. Brentuximab vedotin (marketed as Adcetris) is a targeted drug that specifically seeks out cancer cells carrying a protein called CD30, which is common on Hodgkin’s lymphoma cells. Bendamustine (Treanda) is another chemotherapy agent that works somewhat differently from traditional drugs. Two immunotherapy drugs—nivolumab (Opdivo) and pembrolizumab (Keytruda)—help the body’s own immune system recognize and attack cancer cells by blocking a pathway that lets cancer hide from immune surveillance.^[1][8]

The Role of Stem Cell and Bone Marrow Transplantation

For many people whose Hodgkin’s lymphoma has returned, stem cell transplantation represents the best chance for long-term disease control. This procedure is recommended for patients who didn’t achieve complete remission with their initial treatment, or whose disease came back after initially responding well. The process involves several carefully coordinated steps.^[1]

First, patients receive what’s called second-line chemotherapy—different drug combinations designed to shrink the cancer and prepare the body for transplantation. Once this initial treatment shows the disease is responding, doctors move forward with collecting stem cells. In an autologous transplant, these stem cells come from the patient’s own body, harvested from either bone marrow or circulating blood. The advantage of using one’s own cells is that there’s no risk of rejection, since the body recognizes them as belonging to itself.^[1]

After stem cells are safely collected and stored, patients receive extremely high doses of chemotherapy—much stronger than standard treatment. This intensive chemotherapy is designed to destroy as many cancer cells as possible, but it also wipes out the bone marrow, which is where blood cells are normally produced. This is where the preserved stem cells become crucial: they’re returned to the patient’s body through an infusion, similar to a blood transfusion. Over time, these stem cells travel to the bone marrow and begin producing new, healthy blood cells, essentially rebuilding the blood and immune system.^[1]

In certain situations, doctors may consider an allogeneic stem cell transplant, where the stem cells come from another person—usually a close family member or matched donor. This type of transplant is typically reserved for people whose disease remains active even after an autologous transplant, or who cannot use their own stem cells for medical reasons. Allogeneic transplants carry additional complexity because the donor’s immune cells can sometimes attack the recipient’s tissues, a condition called graft-versus-host disease, but they may also provide an added benefit by helping attack any remaining cancer cells.^[8]

Radiation therapy may also play a role in treating recurrent Hodgkin’s lymphoma, though its use depends on individual circumstances. If the disease has returned in just one or a few lymph node areas and the patient didn’t receive radiation during their first treatment, this focused approach might be recommended. Radiation uses high-energy rays to kill cancer cells in specific locations. It may be given alone or combined with chemotherapy, and it’s sometimes used as part of the preparation process before stem cell transplantation.^[8]

Tomorrow’s Treatments: Innovative Therapies in Clinical Trials

While the cure rate for Hodgkin’s lymphoma is already relatively high compared to many cancers, researchers worldwide continue working to help the patients whose disease proves resistant to standard treatments or returns after transplantation. Numerous promising therapies are currently being studied in clinical trials—carefully controlled research studies where new treatments are tested to determine if they’re safe and effective.^[1]

Clinical trials typically progress through three phases. Phase I trials focus primarily on safety, determining the right dose and identifying side effects in small groups of patients. Phase II trials expand to more patients and examine whether the treatment actually works against the disease. Phase III trials involve large numbers of patients and compare the new treatment directly against current standard therapy to see if it offers better results. Understanding these phases helps patients and families make informed decisions about participating in research.^[4]

One exciting area of investigation involves anti-CD30-CAR T cells. This approach represents a form of cellular immunotherapy, where doctors collect a patient’s own immune cells called T cells, genetically modify them in the laboratory to recognize and attack cancer cells carrying the CD30 protein, then infuse the modified cells back into the patient. These engineered cells act like guided missiles, seeking out and destroying Hodgkin’s lymphoma cells while potentially leaving healthy tissue unharmed.^[1]

Several other immunotherapy drugs are under investigation. Atezolizumab (Tecentriq) works similarly to nivolumab and pembrolizumab, blocking immune checkpoints that cancer cells exploit to avoid detection. This class of drugs, called checkpoint inhibitors, has revolutionized cancer treatment in recent years by unleashing the body’s natural cancer-fighting abilities.^[1]

Researchers are also studying drugs that target specific molecular pathways inside cancer cells. Bortezomib (Velcade) and carfilzomib (Kyprolis) are proteasome inhibitors, meaning they block a cellular machinery that cancer cells need to break down and recycle proteins—essentially clogging up the cancer cell’s waste disposal system until it can no longer survive. Everolimus (Afinitor) targets a different pathway called mTOR, which cancer cells use to fuel their growth and reproduction.^[1]

Additional experimental treatments being tested in clinical trials include a diverse array of substances with different mechanisms of action. These include drugs with code names and chemical names that reflect their specific targets: AB-205, camidanlumab tesirine, camrelizumab, ibrutinib, itacitinib, ipilimumab, lenalidomide, magrolimab, mocetinostat, pralatrexate, romidepsin, ruxolitinib, tislelizumab, and umbralisib. Each of these investigational therapies aims to exploit a different vulnerability in Hodgkin’s lymphoma cells or boost the immune system’s ability to fight the disease.^[4]

Clinical trials for recurrent Hodgkin’s lymphoma are conducted at medical centers around the world, including locations throughout Europe, the United States, and many other countries. Eligibility to participate depends on numerous factors: the extent and characteristics of the disease, previous treatments received, overall health status, and specific requirements of each trial protocol. Patients interested in clinical trials should discuss this option with their oncology team, who can help identify appropriate studies and explain the potential benefits and risks involved.^[4]

Most common treatment methods

• Combination chemotherapy regimens
  • ICE protocol using ifosfamide, carboplatin, and etoposide to attack cancer cells through multiple mechanisms
  • DHAP combining dexamethasone, cisplatin, and cytarabine for patients whose disease has returned
  • ESHAP regimen with etoposide, methylprednisolone, cisplatin, and cytarabine as second-line therapy
  • GVD protocol pairing gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed disease
  • IGEV combination of ifosfamide, gemcitabine, and vinorelbine as salvage therapy
• Targeted therapy
  • Brentuximab vedotin (Adcetris), which specifically targets CD30 protein on lymphoma cells
  • Bendamustine (Treanda), a chemotherapy agent with unique mechanisms of action
• Immunotherapy
  • Nivolumab (Opdivo), a checkpoint inhibitor that helps immune cells recognize cancer
  • Pembrolizumab (Keytruda), another checkpoint inhibitor blocking the PD-1 pathway
• Stem cell transplantation
  • Autologous transplant using patient’s own stem cells after high-dose chemotherapy
  • Allogeneic transplant using donor stem cells for patients with persistent disease
• Radiation therapy
  • Involved site radiation therapy (ISRT) targeting specific lymph node areas
  • Radiation as part of transplant preparation to eliminate remaining cancer cells